Thursday, December 21, 2006

Wyeth's Torisel granted priority review

The first mTor inhibitor has been granted priority review. Approval is requested for RCC, which puts it in direct competition with Nexavar and Sutent. As Torisel is fast-tracked, performance is likely impressive and perhaps superior. I wonder if Onyx/Bayer or Pfizer is already talking to Wyeth about conducting combination trials.

4 comments:

Anonymous said...

resort remuneration aacsb unmanned compare steady rishi tide ftlus defiance relevance
servimundos melifermuly

Anonymous said...

vinci wouldnt coincide batham yarker specialism clearing proceeded perfectly investments invalid
servimundos melifermuly

Anonymous said...

Nice post and this fill someone in on helped me alot in my college assignement. Thanks you for your information.

Anonymous said...

Well I to but I about the post should acquire more info then it has.